Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury

Anesthesiology

Volumn 116, Issue 6, 2012, Pages 1245-1257

  Koeppen, Michael ^a,b   Harter, Patrick N ^c   Bonney, Stephanie ^d   Bonney, Megan ^d   Reithel, Susan ^d   Zachskorn, Cornelia ^c   Mittelbronn, Michel ^c   Eckle, Tobias ^d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR AFFECTING AGENT; BAY 60 6583; TRIPHENYLTETRAZOLIUM; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ADENOSINE A2 RECEPTOR AGONISTS; AMINOPYRIDINES; ANIMALS; BONE MARROW CELLS; CELL TRANSPLANTATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTANT CHIMERIC PROTEINS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEUTROPHILS; PEROXIDASE; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; XANTHINES;

EID: 84861636475     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318255793c     Document Type: Article

References (42)

1. Hausenloy DJ, Yellon DM: Time to take myocardial reperfusion injury seriously. N Engl J Med 2008; 359:518-20
2. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 2007; 357:1121-35
3. Jennewein C, Paulus P, Zacharowski K: Linking inflammation and coagulation: Novel drug targets to treat organ ischemia. Curr Opin Anaesthesiol 2011; 24:375-80
4. Peart JN, Headrick JP: Adenosinergic cardioprotection: Multiple receptors, multiple pathways. Pharmacol Ther 2007; 114:208-21
5. Eltzschig HK: Adenosine: An old drug newly discovered. ANESTHESIOLOGY 2009; 111:904-15
6. Neely CF, DiPierro FV, Kong M, Greelish JP, Gardner TJ: A1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart. Circulation 1996; 94:II376-80
7. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, Wang XQ, French BA, Linden J: Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005; 111:2190-7
8. Cerniway RJ, Yang Z, Jacobson MA, Linden J, Matherne GP: Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. Am J Physiol Heart Circ Physiol 2001; 281:H1751-8
9. Kuno A, Solenkova NV, Solodushko V, Dost T, Liu Y, Yang XM, Cohen MV, Downey JM: Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C. Am J Physiol Heart Circ Physiol 2008; 295:H1288-95
10. Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK: Cardioprotection by ecto-5-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007; 115:1581-90
11. Koeppen M, Eckle T, Eltzschig HK: Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol 2011; 61:145-86
12. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK: A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 2008; 111:2024-35
13. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K: The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 2006; 116:1913-23
14. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL: Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94:1621-8
15. Eckle T, Grenz A, Köhler D, Redel A, Falk M, Rolauffs B, Osswald H, Kehl F, Eltzschig HK: Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol 2006; 291:H2533-40
16. Warth A, Eckle T, Köhler D, Faigle M, Zug S, Klingel K, Eltzschig HK, Wolburg H: Upregulation of the water channel aquaporin-4 as a potential cause of postischemic cell swelling in a murine model of myocardial infarction. Cardiology 2007; 107:402-10
17. Eckle T, Grenz A, Laucher S, Eltzschig HK: A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 2008; 118:3301-15
18. Freitas M, Porto G, Lima JL, Fernandes E: Isolation and activation of human neutrophils in vitro. The importance of the anticoagulant used during blood collection. Clin Biochem 2008; 41:570-5
19. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP: Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in post-hypoxic endothelium: Role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198:783-96
20. Eckle T, Köhler D, Lehmann R, El Kasmi K, Eltzschig HK: Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation 2008; 118:166-75
21. Hu G, Salem MR, Crystal GJ: Role of adenosine receptors in volatile anesthetic preconditioning against neutrophil-induced contractile dysfunction in isolated rat hearts. ANESTHESIOLOGY 2005; 103:287-95
22. Budde JM, Velez DA, Zhao Z, Clark KL, Morris CD, Muraki S, Guyton RA, Vinten-Johansen J: Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res 2000; 47:294-305
23. Nakamura M, Zhao ZQ, Clark KL, Velez DV, Guyton RA, Vinten-Johansen J: A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium. Eur J Pharmacol 2000; 397:197-205
24. Kristo G, Yoshimura Y, Keith BJ, Stevens RM, Jahania SA, Mentzer RM Jr, Lasley RD: Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol 2004; 287:H2746-53
25. Liu Y, Yang X, Yang XM, Walker S, Förster K, Cohen MV, Krieg T, Downey JM: AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts. Basic Res Cardiol 2010; 105:129-37
26. Eltzschig HK, Collard CD: Vascular ischaemia and reperfusion injury. Br Med Bull 2004; 70:71-86
27. Mehta J, Dinerman J, Mehta P, Saldeen TG, Lawson D, Donnelly WH, Wallin R: Neutrophil function in ischemic heart disease. Circulation 1989; 79:549-56
28. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC: Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 1989; 80:1816-27
29. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Eltzschig HK: Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 2009; 10:195-202
30. Chen H, Yang D, Carroll SH, Eltzschig HK, Ravid K: Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. Exp Hematol 2009; 37:533-8
31. Heusch G, Boengler K, Schulz R: Inhibition of mitochondrial permeability transition pore opening: The Holy Grail of cardioprotection. Basic Res Cardiol 2010; 105:151-4
32. Birks EJ, Latif N, Owen V, Bowles C, Felkin LE, Mullen AJ, Khaghani A, Barton PJ, Polak JM, Pepper JR, Banner NR, Yacoub MH: Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001; 104:I233-40
33. Vaddi K, Nicolini FA, Mehta P, Mehta JL: Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation. Circulation 1994; 90:694-9
34. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ, Sabbadini RA: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996; 98:2854-65
35. Schulz R, Aker S, Belosjorow S, Heusch G: TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 2004; 99:8-11
36. Kupatt C, Habazettl H, Goedecke A, Wolf DA, Zahler S, Boekstegers P, Kelly RA, Becker BF: Tumor necrosis factor-alpha contributes to ischemia-and reperfusion-induced endothelial activation in isolated hearts. Circ Res 1999; 84:392-400
37. Niemann JT, Youngquist S, Rosborough JP, Shah AP, Phan QT, Filler SG: Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model. Crit Care Med 2010; 38:1162-7
38. Teng B, Ledent C, Mustafa SJ: Up-regulation of A 2B adenosine receptor in A 2A adenosine receptor knockout mouse coronary artery. J Mol Cell Cardiol 2008; 44:905-14
39. Maxwell MP, Hearse DJ, Yellon DM: Species variation in the coronary collateral circulation during regional myocardial ischaemia: A critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987; 21:737-46
40. Hearse DJ: The elusive coypu: The importance of collateral flow and the search for an alternative to the dog. Cardiovasc Res 2000; 45:215-9
41. Schaper W: Collateral circulation: Past and present. Basic Res Cardiol 2009; 104:5-21
42. Mouse Genome Sequencing Consortium, Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, Antonarakis SE, Attwood J, Baertsch R, Bailey J, Barlow K, Beck S, Berry E, Birren B, Bloom T, Bork P, Botcherby M, Bray N, Brent MR, Brown DG, Brown SD, Bult C, Burton J, Butler J, Campbell RD, Carninci P, Cawley S, Chiaromonte F, Chinwalla AT, Church DM, Clamp M, Clee C, Collins FS, Cook LL, Copley RR, Coulson A, Couronne O, Cuff J, Curwen V, Cutts T, Daly M, David R, Davies J, Delehaunty KD, Deri J, Dermitzakis ET, Dewey C, Dickens NJ, Diekhans M, Dodge S, Dubchak I, Dunn DM, Eddy SR, Elnitski L, Emes RD, Eswara P, Eyras E, Felsenfeld A, Fewell GA, Flicek P, Foley K, Frankel WN, Fulton LA, Fulton RS, Furey TS, Gage D, Gibbs RA, Glusman G, Gnerre S, Goldman N, Goodstadt L, Grafham D, Graves TA, Green ED, Gregory S, Guigo R, Guyer M, Hardison RC, Haussler D, Hayashizaki Y, Hillier LW, Hinrichs A, Hlavina W, Holzer T, Hsu F, Hua A, Hubbard T, Hunt A, Jackson I, Jaffe DB, Johnson LS, Jones M, Jones TA, Joy A, Kamal M, Karlsson EK, Karolchik D, Kasprzyk A, Kawai J, Keibler E, Kells C, Kent WJ, Kirby A, Kolbe DL, Korf I, Kucherlapati RS, Kulbokas EJ, Kulp D, Landers T, Leger JP, Leonard S, Letunic I, Levine R, Li J, Li M, Lloyd C, Lucas S, Ma B, Maglott DR, Mardis ER, Matthews L, Mauceli E, Mayer JH, McCarthy M, McCombie WR, McLaren S, McLay K, McPherson JD, Meldrim J, Meredith B, Mesirov JP, Miller W, Miner TL, Mongin E, Montgomery KT, Morgan M, Mott R, Mullikin JC, Muzny DM, Nash WE, Nelson JO, Nhan MN, Nicol R, Ning Z, Nusbaum C, O'Connor MJ, Okazaki Y, Oliver K, Overton-Larty E, Pachter L, Parra G, Pepin KH, Peterson J, Pevzner P, Plumb R, Pohl CS, Poliakov A, Ponce TC, Ponting CP, Potter S, Quail M, Reymond A, Roe BA, Roskin KM, Rubin EM, Rust AG, Santos R, Sapojnikov V, Schultz B, Schultz J, Schwartz MS, Schwartz S, Scott C, Seaman S, Searle S, Sharpe T, Sheridan A, Shownkeen R, Sims S, Singer JB, Slater G, Smit A, Smith DR, Spencer B, Stabenau A, Stange-Thomann N, Sugnet C, Suyama M, Tesler G, Thompson J, Torrents D, Trevaskis E, Tromp J, Ucla C, Ureta-Vidal A, Vinson JP, Von Niederhausern AC, Wade CM, Wall M, Weber RJ, Weiss RB, Wendl MC, West AP, Wetterstrand K, Wheeler R, Whelan S, Wierzbowski J, Willey D, Williams S, Wilson RK, Winter E, Worley KC, Wyman D, Yang S, Yang SP, Zdobnov EM, Zody MC, Lander ES: Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420:520-62